CRBU - Company ID 0001619856
The table below shows Caribou Biosciences, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$26.98M | -$36.73M | -$37.20M | -$27.94M | -$21.67M | $20.31M |
| Capital expenditure | $72.00K | $1.04M | $1.45M | $2.03M | $723.00K | $22.00K |
| Investing cash flow | $23.98M | $49.38M | $22.96M | $20.70M | -$72.11M | -$22.00K |
| Dividends paid | - | - | - | - |
Caribou Biosciences, Inc. reported operating cash flow of -$110.99M for fiscal year 2025. That is up 19.7% from -$138.20M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from -$32.01M (FY 2019) to -$110.99M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $2.70M | $468.00K | $12.48M | $1.64M | $990.00K | $109.68M |